Introduction

Molecular testing has changed cancer diagnosis, therapy selection, and monitoring by allowing doctors to identify and examine genetic changes that cause cancer development and progression. These advanced tests look at DNA, RNA, and proteins for mutations, rearrangements, and expression patterns that might help predict the future for a patient and guide treatment options. Introducing molecular diagnostics into clinical oncology has greatly improved patient outcomes using personalised medicine techniques, converting potentially deadly diagnoses into treatable diseases for many patients. Modern cancer therapy increasingly depends on extensive genetic information to tailor therapies for specific tumour features, improve therapeutic success, and reduce needless side effects.

Types of Molecular Tests in Oncology

Mutation Analysis Tests

Mutation screening has become critical for cancer diagnosis and therapy, with various approaches used to discover genetic changes that impact disease progression and therapeutic response. Next-generation sequencing (NGS) is commonly used to detect mutations in many genes, resulting in full genomic profiles of tumours. 

Some genetic variations cause conformational changes in the relevant proteins, therefore offering targets for mutation-specific medicines. This process is shown by the BRAF V600E mutation in melanoma, which enables BRAF inhibitor-based targeted treatment. Other modifications, such as ALK, ROS, and RET translocations or MET exon 14 skipping mutations, result in the overexpression of oncogenic enzymes without necessarily affecting their kinase domain interactions with other molecules.¹ These various pathways of oncogenic activation need separate treatment approaches, emphasising the significance of precise mutant characterisation.

Technical techniques for mutation identification are evolving, with more powerful sequencing technologies supporting polymerase chain reaction (PCR), immunohistochemistry (IHC), and fluorescence in situ hybridisation (FISH). These approaches range in sensitivity, specificity, cost, and turnaround time, which affects their clinical use in various circumstances. The approach used for mutation analysis is determined by the precise genetic change studied and the clinical context in which the test results will be employed.

Liquid Biopsy Technologies

Liquid biopsy represents a revolutionary approach to cancer testing that offers significant advantages over traditional tissue biopsies. This minimally invasive technique requires only a standard blood draw (approximately 5 millilitres) to obtain circulating tumour DNA (ctDNA) or other tumour-derived molecules released into the bloodstream. After processing, the plasma component (about 2 millilitres) is analysed for tumour genetic material, providing insight into the molecular characteristics of the cancer without requiring surgical intervention.³

Moreover, liquid biopsies overcome a significant limitation of tissue biopsies, such as tumour heterogeneity. Since most cancers harbour multiple genetic mutations that may vary across different regions of the tumour, traditional tissue sampling might miss important mutations. Liquid biopsies, by capturing DNA released from various parts of the tumour, offer a more comprehensive view of cancer's genetic landscape.³

Perhaps the most interesting element of liquid biopsies is their potential to detect disease progression or treatment resistance long before clinical symptoms appear or imaging investigations indicate variations. While originally focused on lung, breast, and prostate cancers, liquid biopsy technology is projected to be useful for all cancer types as research progresses. These tests are especially useful for continuing illness monitoring and assessing therapy response since they are non-invasive and repeatable.³

Expression-Based Molecular Tests

Expression-based molecular diagnostics use RNA transcripts or protein synthesis patterns to define malignancies and guide treatment decisions. Unlike DNA mutation analysis, which finds genomic abnormalities, expression profiling tells which genes are activated. These tests can be particularly valuable when distinguishing between cancers with similar histological appearances but different clinical behaviours or treatment responses.

In diagnosing malignancies of unknown primary origin (CUPs), RNA expression indicators may outperform standard immunohistochemistry (IHC) examinations. PCR-driven RNA detection is more sensitive than antibody-based approaches and may be used for any expressed gene.¹ Furthermore, unlike antibody production for IHC, which necessitates industrial infrastructure, tailored PCR diagnostic tests may be created in ordinary molecular genetic laboratories. Semi-automated PCR experiments also minimise reading inconsistency compared to IHC, which frequently suffers from interlaboratory errors.¹

Expression profiling has been particularly useful in breast cancer care, where tests like Oncotype DX look at several genes to predict recurrence risk and guide adjuvant therapy selections. Similar techniques are being developed for other cancer types, as researchers recognise that expression patterns frequently supplement mutation studies, providing a more comprehensive picture of tumour biology and possible treatment vulnerabilities.

Integrative Genomic Assessments

Integrative genomic evaluations give a thorough characterisation of cancer genomes by analysing numerous molecular factors at once. These advanced tests go beyond finding specific mutations to evaluating wider genetic characteristics that determine disease behaviour and treatment response. Three significant integrative evaluations are tumour mutation burden (TMB), microsatellite instability (MSI), and homologous recombination deficit (HRD) testing.

Tumour mutation burden measures the overall number of mutations in a tumour's genome, acting as an approximate measure for neoantigen load and possible immunotherapy response. High TMB implies greater tumour antigenicity, implying that cancer is more apparent to the immune system and hence more vulnerable to immune checkpoint inhibitors.¹ Similarly, microsatellite instability testing determines the stability of repeating DNA sequences known as microsatellites, with high instability (MSI-H) suggesting poor DNA mismatch repair. MSI-H status has become an important predictive biomarker for immunotherapy response across different cancer types, serving as a valid selection test for patients having germline mutations in hereditary non-polyposis colorectal cancer (HNPCC)-related genes.¹

The homologous recombination deficiency evaluation measures the tumour's capacity to repair double-strand DNA breaks via the homologous recombination process. Defects in this system, which are frequently linked with BRCA1/2 mutations or other changes in DNA repair genes, make patients vulnerable to PARP inhibitors and platinum-based chemotherapies.¹ These constructed examinations offer a more detailed picture of tumour biology than single-gene assays, allowing for more accurate therapy targeting and better patient outcomes.

Significance in Cancer Care

Diagnosis and Risk Assessment

In clinical practice, the strategy for hereditary cancer testing differs depending on race, family history, and tumour features. In groups with founder mutations, such as Ashkenazi Jews, Eastern Slavs, and Icelanders, where particular BRCA1/2 variations dominate, targeted PCR testing for these prevalent mutations may be useful even if no family cancer syndrome is suspected.¹ In contrast, certain tumour morphologies can direct more specific genetic investigations; for example, triple-negative breast carcinomas demand BRCA1 testing. These molecular insights enable more accurate diagnosis and therapy selection, resulting in much better patient outcomes.

Treatment Selection and Personalisation

Molecular testing has revolutionised cancer treatment by enabling physicians to select therapies based on the specific genetic alterations driving an individual's tumour. This approach, known as stratified medicine, tailors treatment to the molecular profile of the cancer rather than relying solely on histological classification. The identification of actionable mutations—genetic changes that can be targeted with specific drugs—has dramatically improved outcomes for patients with various cancer types, transforming previously fatal diagnoses into manageable chronic conditions in many cases.

Molecular testing has transformed disease monitoring and prognostication in oncology by enabling non-invasive assessment of treatment response and early detection of disease recurrence. Liquid biopsies, which analyse circulating tumour DNA (ctDNA) or other tumour-derived molecules in blood samples, have emerged as powerful tools for tracking disease status over time without requiring repeated tissue sampling.² This approach is particularly valuable for monitoring minimal residual disease—cancer cells that remain after treatment but are undetectable by conventional imaging techniques.

The ability to detect disease progression or treatment resistance through molecular testing significantly predates the appearance of clinical symptoms or radiographic changes. For example, emerging resistance mutations in the EGFR gene can be identified in the blood of lung cancer patients months before radiographic progression occurs.⁴ This early detection window creates opportunities for timely therapeutic adjustments, potentially improving patient outcomes and quality of life. The convenience and tolerability of blood-based testing also facilitate more frequent monitoring compared to tissue biopsies, allowing for more dynamic and responsive treatment planning. 

Clinical Guidelines and Standard of Care

Clinical guidelines have a pivotal role in standardising molecular testing approaches across institutions and ensuring that patients receive appropriate, evidence-based care. These guidelines, developed by professional organisations through a rigorous review of the available evidence, provide clinicians with clear recommendations regarding which patients should undergo testing, which biomarkers should be assessed, and how test results should inform treatment decisions. For non-small cell lung cancer, the College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular Pathology (AMP) have collaborated to produce comprehensive guidelines that the American Society of Clinical Oncology (ASCO) has endorsed.⁴

The concept of "standard-of-care" testing represents molecular tests with proven clinical benefits that haematologists and oncologists routinely order for specific cancer types.⁶ This approach constitutes the majority of molecular testing performed in clinical settings and is distinguished from investigational testing conducted for research purposes or clinical trials.⁶ When considering clinical trials, additional molecular tests may be required as part of the inclusion criteria, highlighting the interface between standard clinical practice and cutting-edge research.⁶ Adherence to established guidelines ensures that patients receive appropriate molecular testing while minimising unnecessary procedures, optimising resource utilisation, and facilitating consistent interpretation of results across different healthcare settings.

Future Directions and Emerging Technologies

The area of molecular testing in oncology is quickly evolving, with various new technologies and methodologies set to revolutionise cancer detection and therapy in the coming years. One of the most notable changes is the move toward agnostic testing, which entails examining all potentially actionable genes across all tumour types rather than just cancer-specific gene panels.¹ This approach recognises that comparable genetic abnormalities can occur in distinct cancer types and may react to the same targeted medicines, broadening therapeutic choices for individuals with uncommon mutations independent of tumour histological origin.

AI and machine learning are other areas in molecular oncology, with potential applications in deciphering complicated genetic data, discovering novel biomarkers, and predicting therapy outcomes.

Liquid biopsy technologies continue to advance, with research expanding beyond their current applications in treatment selection and disease monitoring. According to Miro Venturi, Roche's Global Head of Diagnostics Biomarkers, "In the longer term, liquid biopsies may ultimately be used to catch signs of cancer early, before symptoms arise. This could make a significant difference to the way we understand and treat cancer." As these and other technologies mature, the landscape of molecular testing will continue to evolve, offering increasingly sophisticated tools for personalised cancer care.⁵

Conclusion

Molecular testing has significantly altered cancer care by allowing more detailed classification of tumour biology and tailored therapy choices. From mutation analysis and liquid biopsies to expression profiling and integrated genomic evaluations, molecular testing has a wide range of applications, including hereditary cancer diagnosis, therapy selection, and disease monitoring. The choice of relevant molecular testing necessitates careful assessment of the cancer kind, available treatment choices, clinical recommendations, and the trade-off between advantages and limits. Cancer-specific diagnostic methods have developed to reflect each malignancy's distinct molecular landscapes and therapy options, while professional guidelines enable consistent, evidence-based application. The Molecular Analysis for Precision Oncology Congress 2025 will delve into many of these cutting-edge advancements, highlighting the field's dynamic potential. For both patients and physicians, molecular testing provides promise for more effective, less toxic therapies and better results throughout the cancer spectrum.